Table 2.
Outcomes of atorvastatin-based conservative treatment in 17 super-aged patients with CSDH.
| Case no. | Treatment method | Hematoma clearance | Midline shift (Y/N) | Modified rankin scale score | Markwalder grading scale /glasgow coma scale score | Adverse drug effects | |||
|---|---|---|---|---|---|---|---|---|---|
| Before treatment | After- treatment | Before treatment | After- treatment | Before treatment | After- treatment | ||||
| 1 | ATO | Complete absorption | Y | N | 4 | 2 | 2 | 1 | N |
| 2 | ATO | Calcified | N | N | 5 | 2 | 3 | 1 | N |
| 3 | ATO | Significant absorption | N | N | 2 | 1 | 1 | 0 | N |
| 4 | ATO | Significant absorption | Y | N | 4 | 2 | 2 | 1 | N |
| 5 | ATO | Complete absorption | Y | N | 4 | 1 | 2 | 0 | Hyperglycemia |
| 6 | ATO | Complete absorption | N | N | 5 | 3 | 3 | 1 | Hyperglycemia |
| 7 | ATO + DEX | Significant absorption | Y | N | 2 | 1 | 1 | 0 | Hepatic injury |
| 8 | ATO + DEX | Complete absorption | Y | N | 3 | 0 | 1 | 0 | N |
| 9 | ATO + DEX | Complete absorption | Y | N | 3 | 0 | 2 | 0 | N |
| 10 | ATO + DEX | Complete absorption | N | N | 4 | 1 | 2 | 0 | N |
| 11 | ATO + DEX | Complete absorption | N | N | 4 | 3 | 3 | 1 | Hyperglycemia |
| 12 | ATO + DEX | Complete absorption | N | N | 3 | 0 | 1 | 0 | N |
| 13 | ATO + DEX | Complete absorption | Y | N | 3 | 1 | 2 | 0 | N |
| 14 | ATO + DEX | Significant absorption | Y | N | 3 | 2 | 2 | 1 | N |
| 15 | ATO + DEX | Significant absorption | Y | N | 3 | 1 | 1 | 0 | N |
| 16 | ATO + DEX | Complete absorption | Y | N | 4 | 2 | 3 | 1 | N |
| 17 | ATO + DEX | Calcified | Y | Y | 4 | 3 | 2 | 1 | N |
ATO, atorvastatin; DEX, dexamethasone; Y, yes; N, no.